The Cooper Companies, Inc. Common Stock COO
i
Market dataready · fetched 2026-11-12T15:14:02.421Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T15:13:59.820679422Z
FundamentalsSEC EDGAR · ready · as of 2026-07-31 · fetched 2026-11-12T15:14:01.803428+00:00
The Cooper Companies, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 67.83 | 43.5% | 8.8% | 60.34 | 31.5% | 4.5% |
| 25Δ | 65.68 | 37.7% | 5.5% | 60.75 | 31.4% | 4.1% |
| 30Δ | 64.69 | 35.9% | 4.2% | 61.16 | 31.4% | 3.8% |
| 35Δ | 64.23 | 35.8% | 3.9% | 61.57 | 31.4% | 3.4% |
| 40Δ | 63.78 | 35.7% | 3.5% | 61.98 | 31.4% | 3.1% |
| 45Δ | 63.32 | 35.7% | 3.2% | 62.40 | 31.4% | 2.7% |
| 50Δ | 62.87 | 35.6% | 2.8% | 62.81 | 31.4% | 2.4% |
| 55Δ | 62.41 | 35.6% | 2.5% | 63.22 | 31.3% | 2.0% |
| 60Δ | 61.96 | 35.5% | 2.1% | 63.63 | 31.3% | 1.7% |
| 65Δ | 61.50 | 35.5% | 1.8% | 64.05 | 31.3% | 1.3% |
| 70Δ | 61.04 | 35.4% | 1.4% | 64.46 | 31.3% | 1.0% |
| 75Δ | 60.59 | 35.4% | 1.1% | 64.87 | 31.3% | 0.6% |
| 80Δ | 60.13 | 35.3% | 0.7% | |||
20Δ
- Pseudo strike
- 67.83
- IV
- 43.5%
- B/E move
- 8.8%
- Pseudo strike
- 60.34
- IV
- 31.5%
- B/E move
- 4.5%
25Δ
- Pseudo strike
- 65.68
- IV
- 37.7%
- B/E move
- 5.5%
- Pseudo strike
- 60.75
- IV
- 31.4%
- B/E move
- 4.1%
30Δ
- Pseudo strike
- 64.69
- IV
- 35.9%
- B/E move
- 4.2%
- Pseudo strike
- 61.16
- IV
- 31.4%
- B/E move
- 3.8%
35Δ
- Pseudo strike
- 64.23
- IV
- 35.8%
- B/E move
- 3.9%
- Pseudo strike
- 61.57
- IV
- 31.4%
- B/E move
- 3.4%
40Δ
- Pseudo strike
- 63.78
- IV
- 35.7%
- B/E move
- 3.5%
- Pseudo strike
- 61.98
- IV
- 31.4%
- B/E move
- 3.1%
45Δ
- Pseudo strike
- 63.32
- IV
- 35.7%
- B/E move
- 3.2%
- Pseudo strike
- 62.40
- IV
- 31.4%
- B/E move
- 2.7%
50Δ
- Pseudo strike
- 62.87
- IV
- 35.6%
- B/E move
- 2.8%
- Pseudo strike
- 62.81
- IV
- 31.4%
- B/E move
- 2.4%
55Δ
- Pseudo strike
- 62.41
- IV
- 35.6%
- B/E move
- 2.5%
- Pseudo strike
- 63.22
- IV
- 31.3%
- B/E move
- 2.0%
60Δ
- Pseudo strike
- 61.96
- IV
- 35.5%
- B/E move
- 2.1%
- Pseudo strike
- 63.63
- IV
- 31.3%
- B/E move
- 1.7%
65Δ
- Pseudo strike
- 61.50
- IV
- 35.5%
- B/E move
- 1.8%
- Pseudo strike
- 64.05
- IV
- 31.3%
- B/E move
- 1.3%
70Δ
- Pseudo strike
- 61.04
- IV
- 35.4%
- B/E move
- 1.4%
- Pseudo strike
- 64.46
- IV
- 31.3%
- B/E move
- 1.0%
75Δ
- Pseudo strike
- 60.59
- IV
- 35.4%
- B/E move
- 1.1%
- Pseudo strike
- 64.87
- IV
- 31.3%
- B/E move
- 0.6%
80Δ
- Pseudo strike
- 60.13
- IV
- 35.3%
- B/E move
- 0.7%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 34.19% | |
| 35.66% | |
| 34.77% | |
| 36.31% | |
| 36.56% | |
| 36.53% | |
| 34.59% | |
| 36.86% | |
| 35.22% | |
| 37.02% |
Medical Instruments & Supplies
EMBC
Embecta Corp (EMBC) is a leading medical technology company specializing in innovative insulin delivery systems aimed at enhancing diabetes management. Born from a spin-off of…
More →ICUI
ICU Medical, Inc. develops, manufactures and sells medical devices used in infusion therapy and critical care applications worldwide. The company is headquartered in San Clemente,…
More →ISRG
Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally…
More →KRMD
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the…
More →LMAT
Description unavailable
More →MDLN
Description unavailable
More →